drugset / Trial / NCT07620561
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
Phase 2
Not yet recruiting
15 enrolled
University of Maryland, Baltimore
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
Timeline
- Start
- 2026-06
- Primary completion
- 2027-12
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lebrikizumab | Monoclonal antibody | 250 mg | Subcutaneous |